Opendata, web and dolomites

THUNDER

Development of the Cyclin-Dependent Kinase Inhibitor VS2-370 to Target HIV-associated Malignancies and to Purge Viral Reservoir

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THUNDER project word cloud

Explore the words cloud of the THUNDER project. It provides you a very rough idea of what is the project "THUNDER" about.

men    licencing    induces    clonal    phase    tumor    hiv    confirming    cancer    independently    carry    complete    instrument    vitro    market    advantages    vivo    biotechnology    cdk4    capital    therapy    gmp    savings    patients    fim    strategy    biology    sme    vs2    life    health    unlike    extensive    dependent    innovative    370    anti    sides    remission    first    industry    infection    pathogenetic    exposure    individuals    underlying    hepatitis    models    significantly    opportunity    cure    periods    good    decreased    presently    viral    indirect    pharma    drug    shown    cells    profiles    apoptosis    lot    free    expansion    oncology    reservoir    malignancies    billion    mirroring    quality    suppresses    demonstrated    franchise    file    improvement    anticancer    purge    remissions    tolerability    reached    antiretroviral    tumors    trl6    virostatics    profile    realizing    customer    limits    investigational    expand    indication    infected    functional    similarly    drugs    final   

Project "THUNDER" data sheet

The following table provides information about the project.

Coordinator
VIROSTATICS SRL 

Organization address
address: VIALE UMBERTO I 46
city: SASSARI
postcode: 7100
website: www.virostatics.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.virostatics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIROSTATICS SRL IT (SASSARI) coordinator 50˙000.00

Map

 Project objective

ViroStatics, operating in the biotechnology industry, is developing the innovative drug VS2-370 that targets both HIV-associated cancer and its indirect cause, the viral infection. There is no similar drug, as HIV infection and associated malignancies are presently treated independently, without realizing that they are two sides of the same underlying pathogenetic problem. VS2-370 unique anti-CDK4/6/9 profile not only suppresses HIV, but also limits clonal expansion and induces apoptosis of infected cells, with the potential to purge the viral reservoir. Unlike with currently available antiretroviral therapy (ART) this could lead to a cure of HIV infection (or functional cure, that is to allow long periods of ART-free remission), mirroring the recent success of Hepatitis C cure, and it would similarly open a multi-billion Euro market opportunity. ViroStatics strategy is to develop VS2-370 through the well established pathway of oncology drugs, then to expand the indication to the HIV cure. VS2-370 has reached TRL6 and demonstrated anticancer activity in CDK4/6/9-dependent tumors in relevant in vitro and in vivo models, it has shown good exposure/tolerability profiles, and it has been produced in a GMP lot. After confirming the interest of a Pharma Customer with franchise in Oncology and/or HIV (Phase 1) we will file an Investigational New Drug application and carry out a First in Men (FIM) study through the extensive use of systems biology (Phase 2), thus significantly increasing the value of VS2-370 before out-licencing it to the Pharma Customer. The advantages for the final users (HIV-infected individuals with associated malignancies) will be: tumor- and ART-free remissions, quality of life improvement, decreased side effects associated with ART, cost savings for the patients and the Health Systems.ViroStatics has capital to support its experienced management and to contribute in part to Phase 1 and Phase 2, but needs the SME instrument to complete the FIM study.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THUNDER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THUNDER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More